News and Updates
QART Medical Featured in CTECH by Calcalist
QART's CEO and Co-founder Alon Shalev took part in roundtable discussions at Calcalist's 2023 Israel-Japan conference in Tokyo and presented to senior executives from the Japanese and international tech industries. Following the conference QART Medical was featured in CTECH, Calcalist's journal focusing on Israeli technology and start-up news.
Read moreQART Medical at Chartered Group’s Israeli Disruptive Innovation Showcase in Tokyo
QART Medical presented at Chartered Group’s Israeli Disruptive Innovation Showcase, in Tokyo, Japan on May 30. The showcase is part of the Calcalist and Israel Discount Bank conference that aims to connect the Israeli and Japanese business communities. QART is grateful to Chartered Group for the opportunity to be featured at this conference.
Read moreQART Medical – Approval to Begin Landmark Clinical Study
QART Medical, an ISO13485 certified MedTech company, is proud to announce the receipt of an approval to begin a new clinical study. This study will evaluate its FDA registered flagship product, the Q300™, in real-life conditions for the most commonly performed IVF procedures, Intra Cytoplasmic Sperm Injection (ICSI). The study is an open label, non-randomized, historical-control study, in which quantitative phase microscopy (QPM) will be used in a clinical setting to assist with an IVF procedure. The performance of the Q300™ was previously tested in a multi-center clinical study, which was recently completed to favorable results.
Read moreQART Medical Accepted to NVIDIA Inception
QART Medical is honored to have been accepted into NVIDIA Inception, NVIDIA’s program for startups. NVIDIA is a world leader in Graphics Processing Unit (GPU) technology and has revolutionized the use of GPUs in artificial intelligence applications. The NVIDIA Inception program is designed to help startups with cutting edge AI technology address real-world challenges.
Read moreQART Medical Accepted to the Nextcorps Luminate Startup Accelerator
QART Medical is honored to be accepted to Luminate, the Nextcorps accelerator for startups whose core technology is enabled by optics, photonics, and imaging. QART is one of ten companies chosen by a panel of industry leaders to be part of the 6th Luminate cohort out of 120 applicants.
Read moreQART MEDICAL – SPIE 2023 Startup Challenge
QART Medical is proud to announce its recent win at the International Society for Optics and Photonics (SPIE) 13th annual Startup Challenge. Held annually at SPIE’s flagship event, Photonics West, the Startup Challenge is designed to showcase innovative companies and technologies that use photonics to address unmet needs in healthcare and deep-tech.
Read moreQART MEDICAL has Completed Enrollment in its Multi-Center Clinical Study
QART Medical, Raanana, Israel: QART is excited to announce the completion of patient enrollment in the Feasibility, Usability & Performance multi-center clinical study of the Q300™ system. QART anticipates having final results from this study during Q1 2023. Interim results indicate a favorable agreement between the Q300™ and “gold standard” measurements, good usability, and the great importance of using the Q300™ system, in selecting WHO2021-compliant sperm cells.
Read moreQART MEDICAL – FDA Registration
QART Medical is excited to announce a major milestone for our company: We have registered our flagship product, the Q300™ with the United States Food and Drug Administration (FDA). The Q300™ system empowers embryologists to make objective, quantitative, recorded, and highly-informed decisions about the sperm cells that they intend to select for injection into oocytes during the most prevalent IVF procedure, ICSI (intra cytoplasmic sperm injection).
Read moreQART Medical – Presentation at the JSRM 2022 Conference
QART Medical presented at the 67th Annual Meeting of the Japan Society for Reproductive Medicine, on November 3-4th, 2022 (see: http://www.jsrm.or.jp/en/meetings_sch.html).
The conference took place in the Pacifico Yokohama Conference Center, Tokyo, Japan. The QART team showcased the Q300™ system, which empowers embryologists to make objective, quantitative, recorded, and highly-informed decisions about the sperm cells they select for injection into oocytes during IVF. The QART team was joined by our partners at Chartered Investment Managers who provided excellent in-country support. QART’s groundbreaking technology and the Q300™ system, were presented to embryologists, reproductive-medicine research scientists, hospital administrators and medical device distributors.